Hoffmann-La Roche: Diabetes Mellitus, Type 2 trials
The registry lists 73 Diabetes Mellitus, Type 2 studies with Hoffmann-La Roche as lead sponsor. 7 are open to participants now and 3 have results posted.
Phase 1 19Phase 2 23Phase 3 22No phase 9(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering MedicationsNot yet recruitingNCT07889648Phase 3
- A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 DiabetesRecruitingNCT07843485Phase 3
- A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 DiabetesRecruitingNCT07748208Phase 2
- A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesRecruitingNCT07670416Phase 3
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesRecruitingNCT07351058Phase 3
- A Study to Compare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutide in People With Type 2 DiabetesRecruitingNCT07112872Phase 2
- Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusRecruitingNCT06704672Not applicable
- ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?CompletedNCT01460446Not applicableResults posted
- A Dose-Finding Study of RO4998452 in Patients With Diabetes MellitusCompletedNCT00800176Phase 2Results posted
- A Clinical Study to Evaluate the Use of Episodic, Intensive Blood Glucose Monitoring in Persons With Non-insulin Treated Type 2 DiabetesCompletedNCT00674986Not applicableResults posted
- A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or ObesityActive, not recruitingNCT07137585Phase 1
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusCompletedNCT06628362Phase 2
- Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes MellitusCompletedNCT05814107Phase 1
- A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT05110846Phase 2
- A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood GlucoseCompletedNCT04973111Phase 1
- A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver DiseaseCompletedNCT03060538Phase 1
- A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.CompletedNCT02268929Not applicable
- A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477CompletedNCT02164266Phase 1
- A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.CompletedNCT02156349Not applicable
- European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.CompletedNCT02105103Not applicable
- A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.CompletedNCT02103595Not applicable
- A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With MetforminWithdrawnNCT01951183Phase 2
- A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)WithdrawnNCT01893242Phase 3
- A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic TherapyCompletedNCT01871428Phase 3
- A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin MonotherapyCompletedNCT01871415Phase 3
- A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes MellitusCompletedNCT01789788Phase 1
- A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With MetforminCompletedNCT01729403Phase 2
- A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose AbnormalitiesCompletedNCT01715818Phase 3
- A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin TherapyCompletedNCT01691989Phase 3
- A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin AloneCompletedNCT01691846Phase 3
- A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic TherapyCompletedNCT01691755Phase 3
- A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery DiseaseCompletedNCT01680978Phase 2
- Study of RO6807952 in Patients With Diabetes Mellitus Type 2TerminatedNCT01516476Phase 2
- A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With LisinoprilCompletedNCT01398267Phase 1
- A Study of RO6807952 in Patients With Diabetes Mellitus Type 2CompletedNCT01358929Phase 1
- Accu-Chek missiOn: SMBG in Patients With diAbetes on inSulin Study (COMPASS) - Multiple Center, Open, and Non-randomized StudyCompletedNCT01130480Not applicable
- A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination TherapyTerminatedNCT01051011Phase 3
- A Study of Single Doses of RO4998452 in Patients With Type 2 DiabetesCompletedNCT01044017Phase 1
- A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal ImpairmentCompletedNCT01043029Phase 2
- A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusCompletedNCT01042769Phase 3
- A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular DiseaseCompletedNCT01018173Phase 3
- A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.CompletedNCT01017302Phase 1
- A Study of RO5095932 in Patients With Type 2 Diabetes MellitusCompletedNCT00961909Phase 1
- A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal ImpairmentCompletedNCT00933972Phase 1
- A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 DiabetesCompletedNCT00909597Phase 3
- A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin MonotherapyCompletedNCT00823992Phase 3
- A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of MetforminCompletedNCT00823680Phase 2
- A Study of Taspoglutide in Type 2 Diabetic PatientsCompletedNCT00811460Phase 1
- A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 DiabetesCompletedNCT00809705Phase 3
- A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.CompletedNCT00755287Phase 3
- A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.CompletedNCT00754988Phase 3
- A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.CompletedNCT00744926Phase 3
- A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.CompletedNCT00744367Phase 3
- A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.CompletedNCT00717457Phase 3
- A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.CompletedNCT00682097Phase 1
- PRISMA Study (Prospective, Randomized Trial on Intensive Self-Monitoring Blood Glucose Management Added Value in Non-Insulin Treated Type 2 Diabetes Mellitus Patients)CompletedNCT00643474Not applicable
- A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.CompletedNCT00517465Phase 1
- A Study of Dipeptidyl-peptidase IV (DPP-IV) RO4876904 in Patients With Type 2 Diabetes.CompletedNCT00502710Phase 2
- A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.CompletedNCT00461058Phase 2
- A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.CompletedNCT00461006Phase 2
- A Titration Study of a Glucagon-Like Peptide-1 (GLP-1) Analogue in Patients With Type 2 Diabetes Treated With Metformin.CompletedNCT00460941Phase 2
- A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.TerminatedNCT00437606Phase 1
- A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.CompletedNCT00423501Phase 2
- A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.CompletedNCT00388986Phase 1
- A Study of Aleglitazar in Patients With Type 2 DiabetesCompletedNCT00388518Phase 2
- A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.CompletedNCT00377442Phase 1
- A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.CompletedNCT00368368Phase 1
- A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.CompletedNCT00366379Phase 2
- A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.CompletedNCT00316758Phase 2
- A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of MetforminCompletedNCT00266253Phase 2
- A Study of GK Activator (2) in Patients With Type 2 Diabetes MellitusCompletedNCT00266240Phase 2
- A Study of DPP-IV Inhibitor in Patients With Type 2 DiabetesCompletedNCT00111670Phase 2
- A Study of DPP-IV Inhibitor in Patients With Type 2 DiabetesCompletedNCT00111631Phase 2